FJ5002: A potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis

Cancer Research

Volumn 59, Issue 16, 1999, Pages 4004-4011

  Naasani, Imad ^a,b   Seimiya, Hiroyuki ^a   Yamori, Takao ^a   Tsuruo, Takashi ^a,b  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; BERBERINE; ENZYME INHIBITOR; FJ 5002; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL GROWTH; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; PYRIDINES; TELOMERASE; THIAZOLES;

EID: 0033566694     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 81: 1088-1092, 1989.
2. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., and Vaigro-Wolff, A. Feasibility of a high-flux drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83: 757-766, 1991.
3. Yamori, T. A human cell line panel for screening anticancer drugs. Gan To Kagaku Ryoho (Japanese), 24: 129-135, 1997.
4. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Jr., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Viswanadhan, V. N., Johonson, G. S., Wittes, R. E., and Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science (Washington DC), 275: 343-349, 1997.
5. Blackburn, E. H. Structure and function of telomeres. Nature (Lond.), 350: 569-573: 1991.
6. Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., and Bacchetti, S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J., 11: 1921-1929, 1992.
7. Wright, W. E., Brassiskyte, D., Piatyszek, M. A., and Shay, J. W. Experimental elongation of telomeres extends the lifespan of immortal × normal cell hybrids. EMBO J., 15: 1734-1741, 1996.
8. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Washington DC), 266: 2011-2015, 1994.
9. Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A., and Shay, J. W. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med., 1: 249-255, 1995.
10. Healy, K. C. Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Oncol. Res., 7: 121-130, 1995.
11. Raymond, E., Sun, D., Chen, S-F., Windle, B., and Vonhoff, D. D. Agents that target telomerase and telomeres. Curr. Opin. Biotechnol., 7: 583-591, 1996.
12. Holt, S. E., Shay, J. W., and Wright, W. E. Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol., 14: 836-839, 1996.
13. Kim, N. W. Clinical implications of telomerase in cancer. Eur. J. Cancer, 33: 781-786, 1997.
14. Counter, C. M., Hahn, W. C., Wei, W., Caddle, S. D., Beijersbergen, R. L., Lansdorp, P. M., Sedivy, J. M., and Weinberg, R. A. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. USA, 95: 14723-14728, 1998.
15. Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst., 82: 1113-1118, 1990.
16. Naasani, I., Seimiya, H., and Tsuruo, T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun., 19: 391-396, 1998.
17. Wright, W. E., Shay, J. W., and Piatyszek, A. M. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res., 23: 3794-3795, 1995.
18. Krupp, G., Kuhne, K., Tamm, S., Klapper, W., Heidorn, K., Rott, A., and Parwaresch, R. Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust 'TRAP' assay. Nucleic Acids Res., 25: 919-921, 1997.
19. Therkelsen, A. G., Nielsen, A., Koch, J., Hindkjær, J., and Kølvraa, S. Staining of human telomeres with primed in situ labeling (PRINS). Cytogenet. Cell Genet., 68: 115-118, 1995.
20. Bryan, T. M., Englezou, A., Dunham, M. A., and Reddel, R. R. Telomere length dynamics in telomerase-positive immortal human cell populations. Exp. Cell. Res., 239: 370-378, 1998.
21. Mergny, J. L., Phan, A. T., and Lacroix, L. Following G-quartet formation by UV-spectroscopy. FEBS Lett., 11: 74-78, 1998.
22. Koya, K, Li., Y., Wang, H., Ukai, T., Tatsuta, N., Kawakami, M., Shishido, T., and Chen, L. B. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res., 56: 538-543: 1996.
23. Salazar, M., Thompson, B. D., Kerwin, S. M., and Hurley, L. H. Thermally induced DNA-RNA hybrid to G-quadruplex transitions: possible implifications for telomere synthesis by telomerase. Biochemistry, 35: 16110-16115, 1996.
24. Sharma, S., Raymond, E., Soda, H., Sun, D., Hiłsenbeck, S. G., Sharma, A., Izbicka, E., Windle, B., and Von Hoff, D. D. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann. Oncol., 8: 1063-1074, 1997.
25. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., Pereira-Smith, O., and Peacocke, M. A biomarker that identifies senescent human cells in culture and aging skin in vivo. J. Proc. Natl. Acad. Sci. USA, 92: 9363-9367, 1995.
26. Bond, J. A., Haughton, M. F., Rowson, J. M., Smith, P. J., Gire, V., Wynford-Thomas, D., and Wyllie, F. S. Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol. Cell. Biol. 19: 3103-3114, 1999.
27. Ishibashi, T., and Lippard, S. J. Telomere loss in cells treated with cisplatin, Proc. Natl. Acad. Sci. USA, 95: 4219-4223, 1998.
28. Coffey, D. S. Self-organization, complexity and chaos: the new biology for medicine. Nat, Med., 4: 882-885, 1998.
29. Strahl, C., and Blackburn, E. H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol., 16: 53-65, 1996.
30. Nakamura, T. M., Cooper, J. P., and Cech, T. R. Two modes of survival of fission yeast without telomerase. Science (Washington DC), 282: 493-496, 1998.
31. Kaufmann, W. K., and Paules, R. S. DNA damage and cell cycle checkpoints. FASEB J., 10: 238-247, 1996.